A Selection of Dr. Moghimi's peer-reviewed publications:

1. Moghimi, S.M., Simberg, D. and Anchordoquy, T.J. (2020) Tuning the engines of nanomedicine. Molecular Therapy 28: 693–694.

2. Pannuzzo, M., Esposito, S., Wu, L-P., Key, J., Aryal, S., Celia, C., di Marzio, L., Moghimi, S.M. and Decuzzi, P. (2020) Overcoming nanoparticle-mediated complement activation by surface PEG-pairing.  Nano Letters (in press) https://doi.org/10.1021/acs.nanolett0c01011.

3. Vu, V.P., Gifford, G.B., Chen, F., Benasutti, H., Wang, G., Groman, E.V., Scheinman, R., Saba, L., Moghimi, S.M. and Simberg, D. (2019) Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles. Nature Nanotechnology 14: 260–268.

4. Hall, A., Maynard, S., Wu, L-P., Merchut-Maya, J. M., Strauss, R., Jäättelä, M., Moghimi, S. M. and Bartek, J. (2019) Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. Journal of Controlled Release 309: 158–172.

5. Gifford, G., Vu, V.P., Banda, N.K., Holers, V.M., Wang, G., Groman, E., Backos, D., Scheinman, R., Moghimi, S.M. and Simberg, D. (2019) Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. Journal of Controlled Release 302: 181–189.

6. Moghimi, S.M., Simberg, D., Skotland, T., Yaghmur, A. and Hunter, A.C. (2019) The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. Journal of Pharmacology and Experimental Therapeutics 370: 581–592.

7. Moghimi, S.M. and Peer, D. (2019) Reprogramming the lymphocytes axis for advanced immunotherapy. Advanced Drug Delivery Reviews 141: 1–2. 

8. Rahbarizadeh, F., Ahmadvand, D. and Moghimi, S.M. (2019) CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews 141: 41–46.

9. Tavano, R., Gabrielli, L., Lubian, E., Fedeli, C., Visentin, S., De Laureto, P. P., Arrigoni, G., Geffner-smith, A., Chen, F., Simberg, D., Morgese, G., Benetti, E.M., Wu, L., Moghimi, S.M., Mancin, F. and Papini, E. (2018) C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly(2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano 12: 5834–5847.

10. Moghimi, S.M. (2018) Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discovery Today 23: 1034–1042.

11. Moghimi, S.M. and Howard. K.A. (2018) Targeting biological barriers: turning a wall into a therapeutic springboard. Molecular Therapy 26: 933–944.

12. Griffin, J.I., Wang, G., Smith, W.J., Vu, V.P., Scheinman, R., Stitch, D., Moldovan, R., Moghimi, S. M. and Simberg, D. (2017) Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy. ACS Nano 11: 11584–11593.

13. Wibro, P.P., Anselmo, A. C., Nilsson, P., Sarode, A., Gupta, V., Urbanics, R., Szebeni, J., Hunter, A.C., Mitragotri, S., Mollnes, T.E.  and Moghimi, S.M. (2017) By-passing injection reactions to nanoparticles through shape modification and attachment to erythrocyte. Nature Nanotechnology 12: 589–594.

14. Ordóñez-Gutiérrez, L., Posado-Fernández, A., Ahmadvand, D., Lettiero, B., Wu, L. P., Antón, M., Flores, O., Moghimi, S. M. and Wandosell, F. (2017) ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer’s disease is restricted to aged animals. Biomaterials 112: 141–152.

15. Chen, F., Wang, G., Griffin, J., Brenneman, B., Banda, N. K., Holers, V.M. , Backos, D. S., Wu, L-P., Moghimi, S.M. and Simberg, D. (2017) Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nature Nanotechnology 12: 387–393.

16. Anchordoquy, T., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Debrovolskaia, M., Farhangrazi, Z.S., Farrell,  D., Gabizon, A., Ghandehari, H.R., Godin, B.,  La-Beck, N.H., Ljubimova, J., Moghimi, S.M., Pagliano, L., Park, J-H., Peer, D., Ruoslahti, E., Serkova, N.J. and D. Simberg (2017) Mechanisms and barriers in anti-cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 11: 12–18.

17. Moghimi, S.M. and Simberg, D. (2017) Complement activation turnover on surfaces of nanoparticles. Nano Today 15: 8–10.

18. Wibroe, P. P., Petersen, S. V., Bovet, N., Laursen, B. W. and Moghimi, S. M. (2016) Soluble and immobilized graphene oxide activates the complement differently dependent on surface oxidation state. Biomaterials 78: 20–126.

19. Inturi, S., Wang, G., Chen, F., Banda, N. K., Holers, V.M., Moghimi, S.M. and Simberg, D. (2015) Modulatory role of surface coating of superparamagnetic iron oxide nanoworms on complement opsonisation and leukocytes uptake. ACS Nano 9: 10758–10768.

20. Whitehead, B., Wu, L-P., Hvam, M. L., Aslan, H., Dong, M., Dyrskjøt, L., Ostenfeld, M. S., Moghimi, S. M. and Howard, K. A. (2015). Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. Journal of Extracellular Vesicles 4: 29685 – http://dx.doi.org/10.3402/jev.v4.29685.

21. Rahimi Jamnani, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Rahbrizadeh, F., Parhamifar, L. and Moghimi, S. M. (2014) T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumour-directed oligoclonal T cell therapy. Biochimica et Biophysica. Acta – General Subjects 1840: 378–386.

22. Andersen, A. J., Robinson, J. T., Dai, H., Hunter, A. C., Andresen, T. L. and Moghimi, S. M. (2013) Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7: 1108–1119.

23. Benjaminsen, R.V., Mattebjerg, M.A., Henriksen, J. R., Moghimi, S.M. and Andresen, T.L. (2013) The possible ‘proton-sponge’ effect of polyethylenimine does not include change in lysosomal pH. Molecular Therapy 21: 147–157.

24. Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kona, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S.M., Tvaroska, I., Couvreur, P. and Andrieux, K. (2012) PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: towards engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano 6: 5897–5908.

25. Moghimi, S.M., Hunter, A.C. and Andresen, T.L. (2012) Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annual Review of Pharmacology and Toxicology 52: 481–503.

26. Moghimi, S.M., Peer, D. and Langer R. (2011) Re-shaping the future of nanopharmaceuticals: ad iduicium. ACS Nano 5: 8454–8458.

27. Hamad, I., Al-Hanbali, O., Hunter, A.C., Rutt, K.J., Andresen, T.L. and Moghimi, S. M. (2010) Distinct polymer architecture mediates switching of complement activation pathways at nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4: 6629–6638.

28. Moghimi, S.M. and Hunter, A. C. (2010) Complement monitoring of carbon nanotubes. Nature Nanotechnology 5: 382–382.

29. Hamad, I., Hunter, A. C., Szebeni, J. and Moghimi, S. M. (2008) Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology 46: 225–232.

30. Mukhopadhyay, R., Al-Hanbali, O., Pillai, S., Hemmersam, A.G., Meyer, R.L., Hunter, A.C., Rutt, K.J., Besenbacher, F., Moghimi, S.M. and Kingshott, P. (2007) Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. Journal of the American Chemical Society 129: 13390–13391. 

31. Moghimi, S.M., Hamad, I., Andresen, T.L., Jorgensen, K. and Szebeni, J. (2006) Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB Journal 20: 2591–2593. Full-Length Article: https://doi.org/10.1096/fj.06.6186fje 

32. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.

33. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2005) Nanomedicine: current status and future prospects. FASEB Journal 19: 311–330.

34. Moghimi, S.M., Symonds, P., Murray, J.C., Hunter, A.C., Debska, G. and Szewczyk, A. (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. Molecular Therapy 11: 990–995.

35. Moghimi, S.M., Hunter, A.C., Murray, J.C. and Szewczyk, A. (2004) Cellular distribution of nonionic micelles. Science 303: 626–627. 

36. Moghimi, S.M. and Szebeni, J. (2003) Stealth liposomes and nanoparticles: critical issues on protein-binding properties, activation of proteolytic blood cascades and intracellular fate. Progress in Lipid Research 42: 463–478.

37. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2001) Long circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews 53: 283–318.

38. Moghimi, S. M. (2006) The effect of methoxyPEG chain length and molecular architecture on lymph node targeting of immuno-PEG-liposomes. Biomaterials 27: 136–144.

39. Moghimi, S. M. and Murray, J. C. (1996) Poloxamer-188 re-visited: a potentially valuable immune modulator? Journal of the National Cancer Institute 88: 766–768.

40. Moghimi, S. M., Hawley, A. E., Christy, N. M., Gray, T., Illum, L. and Davis, S. S. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of lymph nodes. FEBS Letters 344: 25–30. 

41. Porter, C. J. H., Moghimi, S. M., Illum, L., Davis, S. S. (1992) The polyoxyethylene/ polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Letters 68: 121–126.